ID: ALA20518

Max Phase: Preclinical

Molecular Formula: C18H11ClFN3O3S

Molecular Weight: 403.82

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)Cc1nn(Cc2nc3cc(Cl)cc(F)c3s2)c(=O)c2ccccc12

Standard InChI:  InChI=1S/C18H11ClFN3O3S/c19-9-5-12(20)17-14(6-9)21-15(27-17)8-23-18(26)11-4-2-1-3-10(11)13(22-23)7-16(24)25/h1-6H,7-8H2,(H,24,25)

Standard InChI Key:  JLTBDEFBWMDXKP-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.82

Molecular Weight (Monoisotopic): 403.0194

AlogP: 3.47

#Rotatable Bonds: 4

Polar Surface Area: 85.08

Molecular Species: ACID

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.87

CX Basic pKa: 2.45

CX LogP: 3.45

CX LogD: 0.38

Aromatic Rings: 4

Heavy Atoms: 27

QED Weighted: 0.56

Np Likeness Score: -1.81

References

1. Mylari BL, Larson ER, Beyer TA, Zembrowski WJ, Aldinger CE, Dee MF, Siegel TW, Singleton DH..  (1991)  Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.,  34  (1): [PMID:1899452] [10.1021/jm00105a018]

Source

Source(1):

• Scientific Literature